Abstract: Objective To investigate the correlation between different molecular subtypes for breast cancer(BC) and the therapeutic effect and prognosis of dose dense docetaxel neoadjuvant chemotherapy. Methods A total of 76 patients with operable,histologically confirmed BC received 4 cycles of dose dense docetaxel neoadjuvan chemotherapy between March 2007 and December 2009.The expression of estrogen receptor (ER) progesterone receptor (PR),Her-2 and Ki67 were detected by immunohistochemical method and fluorescence in-situ hybridization before neoadjuvan chemotherapy.The patients were classified into 4 subtypes.The primary end points were clinical response rate(RR),3-year disease-free survival rates(DFS) and overall survival rate(OS) for every subtypes.Secondary end points were adverse events,pathologic complete response(pCR). Results In a total of 76 patients,the most common grade 3-4 toxicities were neutropenia (28.9%),liver function (10.5%),cutaneous (9.2%)，myalgia and arthralgia(6.6%),respectively.The pCR was 5 cases.The RR of Luminal A,Luminal B,Her-2+and triple negative were 86.1%,82.4%,100% and 100%,respectively（P=0.256）.The 3-year disease-free survival rates and overall survival rate of luminal A,luminal B,Her-2+and triple negative were 94%,97%,88%,94,70%,70%,69% and 69%,respectively.Compared with the 3-year DFS,OS of Luminal A and Her-2+,Luminal A and triple negative,there were significant difference(P<0.05). Conclusion Docetaxel 75 mg/m2 neoadjuvan chemotherapy regimen is safe.The prognosis of Luminal A is better than Her-2+ and triple negative.